Comparative Pharmacology
Head-to-head clinical analysis: CYCLAINE versus LIDOCATON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAINE versus LIDOCATON.
CYCLAINE vs LIDOCATON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclaine is a local anesthetic that reversibly blocks nerve conduction by decreasing the permeability of the neuronal membrane to sodium ions, thereby stabilizing the membrane and preventing the initiation and transmission of electrical impulses.
Lidocaine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, inhibiting the inward sodium current, thereby stabilizing cardiac membranes, decreasing automaticity, and increasing the fibrillation threshold. It also acts as a local anesthetic by reversibly blocking nerve impulse propagation.
0.2–0.4 mg/kg IV for induction; 0.5–1.5 mg/kg/h IV infusion for maintenance.
Lidocaine: Initial IV bolus 1-1.5 mg/kg, then IV infusion 1-4 mg/min. Adjust for arrhythmia suppression.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged with hepatic impairment.
Terminal half-life 1.5–2 hours (adults); prolonged in heart failure (up to 4–6 hours) or hepatic impairment (up to 8 hours).
Renal: minimal (<5% unchanged); biliary/fecal: >70% as metabolites; small amount exhaled as CO2.
Renal: ~90% as metabolites (major metabolite 4-hydroxyxylidine) and ~10% unchanged. Biliary/fecal: <5%.
Category C
Category C
Local Anesthetic
Local Anesthetic